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Aortic stenosis (AS) is the most frequent type of valve
disease in Europe and North America and often requires
hospitalization and intervention. Until the last decade, the
only curative treatment available was surgical aortic valve
replacement (AVR) but since 2002, transcatheter aortic
valve implantation (TAVI) has emerged as an alternative
treatment for selected high-risk patients. Thus, the evalua-
tion of the number of potential candidates for this new
technique has important public health implications.
See page 1002
Osnabrugge et al. (1), in this issue of the Journal, report
a comprehensive literature search to assess the prevalence of
aortic stenosis in patients over the age of 75 years. They
reviewed 7 studies including 9,723 patients and found a high
prevalence of severe AS: 3.4%. This number clearly illus-
trates the magnitude of the problem (2). Despite differences
in the degree and deﬁnition of AS severity between series,
this estimation seems robust because it relies on consistent
estimations across studies.
The second ﬁnding is that 75% of the patients with severe
AS were considered to be symptomatic. There could be
caveats in this estimation because, in the elderly population,
it could be difﬁcult to establish that the symptoms are
related to AS and not to comorbidities. In addition, many
patients who claim to be asymptomatic are in fact symp-
tomatic when exercise testing is performed.
As regards the management strategy, this study showed
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Medtronic.AS were not treated surgically. This ﬁgure stresses the under-
treatment of high-risk patients with AS (3). Here, again,
a word of caution is necessary because the studies quoted are
heterogeneous as regards the period of time covered, the
evaluation of the degree of stenosis, and symptoms, which
may result in marked differences in the percentages of
patients who were not referred to surgery.
The ultimate ﬁnding is that simulations suggest that
among the patients not treated surgically, 40% received
TAVI. That led the investigators to extrapolate that as many
as 300,000 elderly patients with AS are TAVI candidates
across Europe and the United States. Despite the careful
methodology used in this study, in particular analysis of
sensitivity that limits the impact of the extrapolation, it
requires some comment.
The estimation of the percentage of patients referred for
TAVI has limitations due to the limited number of series
and, more importantly, the temporary variations with their
inherent consequences on indications for intervention and
the choice of technique. For example, in the very early days,
the procedure was only performed on inoperable patients,
whereas we are now seeing an undesired shift to performing
the procedure for intermediate-risk patients despite the
current recommendations (4). In addition, patients may be
denied surgery according to inappropriate criteria; in other
words, not because of a high risk for surgery but because of
older age or left ventricular dysfunction without comorbid-
ities, and these patients should be considered as candidates
for surgery rather than TAVI for the time being.
More generally speaking it is acceptable to state that 40%
of patients in the study should be assessed for the need and
feasibility of TAVI; however, it is difﬁcult to precisely
evaluate the number of “TAVI candidates” from meta-
analysis because the decision for TAVI requires a careful
individual evaluation of each patient in this population by
a heart team composed of cardiologists, surgeons, imaging
specialists, and other noncardiologists if necessary. The
decision-making process by the heart team should supersede
a strategy based only on risk scores, which are helpful but far
from perfect for patient selection in this patient population,
in part because surgery may be high risk or even contra-
indicated because of comorbidities, which are not included in
the contemporary risk scores (4). We have to work to deﬁne
not only better risk scores to assess the risk of surgery in the
contemporary population but also speciﬁc TAVI risk scores.
Among the patients denied for surgery, some should
not be treated by TAVI because their life expectancy is too
short due to comorbidities, and it is unlikely, and probably
undesirable, that a larger proportion of such patients will
be treated by TAVI in the future because the procedure
would not improve their life expectancy or, even more so,
their quality of life. We need here to reﬁne the analysis of
co-morbidities and especially the evaluation of frailty.
Conversely, it is likely that the indication will be extended to
lower risk patients because of a better knowledge of the
results of TAVI with longer term follow-up and more reﬁned
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1014technology. Although we do not yet have sufﬁcient evi-
dence, new trials such as PARTNER (Placement of Aortic
Transcatheter Valves) II and SURTAVI (Surgical Replace-
ment and Transcatheter Aortic Valve Implantation) are on
the way to answer this question. We also need studies to
investigate whether the indications for TAVI can be ex-
tended to patients with relative contraindications such as
low left ventricular ejection fraction, associated coronary
disease, bicuspid valve, bioprosthesis failure, and perhaps
aortic regurgitation. Overall, the respective use of TAVI
versus surgery will increase in the future, although it is too
early to say for certain when and, more importantly, to what
extent.
Finally, the regulatory aspects signiﬁcantly impact the use
of TAVI as shown by the differences in the use of TAVI in
Europe and the United States: the estimation of the
proportion of patients treated by TAVI is 40% in the
European Union and 27% in the United States. In addition,
in Europe, where this technology is widely used, the
economic situation reﬂected by the volume-indexed gross
domestic product and reimbursement modalities does have
an important impact on the use of TAVI and explains
variations across countries: in 2011, TAVI was performed in
97 per million inhabitants in Germany versus 35 in France
and 19 in the United Kingdom (personal communication, D.
Mylotte, MD, American College of Cardiology, San Fran-
cisco, March 2013).
Thus, taking into account the magnitude of the public
health problem that is represented by the management of
elderly patients with severe AS and the possible implications
of widening the indications for TAVI in the years to come, it
is imperative to improve our knowledge. The study by
Osnabrugge et al. (1) is an important contribution; however,
as TAVI moves forward, we need actual ﬁgures and must
perform contemporary prospective observational studies to
accurately assess the number of possible candidates for TAVI.
These studies should include systematic and precise assess-
ment of the severity of AS using echocardiography according
to the recommendations of the scientiﬁc societies (4). These
registries should be “global,” that is to say, they should
prospectively record all types of management: patients treated
medically, by TAVI, or by surgery.
There are several comprehensive nationwide registries for
TAVI (5). There are fewer registries including surgery and
TAVI, such as the recent German Aortic Valve Registryin Germany (personal communication, C. W. Hamm, ESC
Annual Congress, August 2012), which shows that TAVI
represents 28% of the total interventions in AS. However,
we lack registries showing all management strategies, with
the exception of a Spanish registry (personal communica-
tion, M. Martinez-Selles, ESC Annual Congress, August
2012) prospectively performed in octogenarians with symp-
tomatic AS and showing that 46% were managed medically,
26% by AVR, and 28% by TAVI.
These efforts should be encouraged at the level of the
scientiﬁc societies. Such evaluation, which should be dy-
namic to take into account the potential evolution of indi-
cations and thereby changes in patient population, is the
only means of ascertaining the contemporary impact of AS
management on public health and also of checking consis-
tency between guidelines and practice. It would also be
a useful complement to the randomized trials to provide
us with the best evidence to support TAVI and allow the
harmonious development and dissemination of this prom-
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